Gene therapy in epilepsy.
Results from animal models suggest gene therapy is a promising new approach for the treatment of epilepsy. Several candidate genes such as neuropeptide Y and galanin have been demonstrated in preclinical studies to have a positive effect on seizure activity. For a successful gene therapy-based treatment, efficient delivery of a transgene to target neurons is also essential. To this end, advances have been made in the areas of cell transplantation and in the development of recombinant viral vectors for gene delivery. Recombinant adeno-associated viral (rAAV) vectors in particular show promise for gene therapy of neurological disorders due to their neuronal tropism, lack of toxicity, and stable persistence in neurons, which results in robust, long-term expression of the transgene. rAAV vectors have been recently used in phase I clinical trials of Parkinson's disease with an excellent safety profile. Prior to commencement of phase I trials for gene therapy of epilepsy, further preclinical studies are ongoing including evaluation of the therapeutic benefit in chronic models of epileptogenesis, as well as assessment of safety in toxicological studies.
Riban
Véronique
V
Department of Molecular Virology, The Ohio State University, Biological Research Tower, Columbus, Ohio, USA.
Fitzsimons
Helen L
HL
During
Matthew J
MJ
D017690:Cell Transplantation / Q000379:methods; D053595:Embryonic Stem Cells / Q000637:transplantation; D004827:Epilepsy / Q000235:genetics* / Q000628:therapy*; D005240:Feasibility Studies; D019004:Galanin / Q000235:genetics; D018014:Gene Transfer Techniques; D005814:Genes, Viral / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D009478:Neuropeptide Y / Q000235:genetics
D009478:Neuropeptide Y; D019004:Galanin